ADC Therapeutics S.A.

Clinical trials sponsored by ADC Therapeutics S.A., explained in plain language.

ADC Therapeutics S.A. ADCT NYSE

A commercial-stage biotech company developing antibody-drug conjugates for cancer.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New cocktail of cancer drugs shows promise for tough lymphoma Results expected Mar 2027 (estimated) May already have reported ↗

Browse trials soon ready across all sponsors →

Not yet finished but already full! 2 Terminated 1

Liver-Friendly lymphoma treatment? new drug dosing study offers hope

Disease control Stopped early

This study tests the safety and best dose of loncastuximab tesirine, a targeted antibody-drug conjugate, in people with relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma who also have moderate or severe liver impairment. The goal is to find a dosi…

Phase 1 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control

Last updated Jul 22, 2026 00:00 UTC

ADC Therapeutics S.A.

Upcoming readouts

Liver-Friendly lymphoma treatment? new drug dosing study offers hope